<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168091">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01811199</url>
  </required_header>
  <id_info>
    <org_study_id>09.2011.0024</org_study_id>
    <nct_id>NCT01811199</nct_id>
  </id_info>
  <brief_title>Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2α and LTC4 Levels</brief_title>
  <acronym>no</acronym>
  <official_title>Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2α and LTC4 Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marmara University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marmara University</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Dexamethasone reduces postoperative emesis in thyroidectomy and mastectomy
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has been done to further study the effectiveness of dexamethasone  in the
      prevention of postoperative emesis after breast and thyroid surgery and at the same time,
      the mechanism of action was investigated. In this prospective, randomized controlled trial
      it was  hypothesized that corticosteroids exert their antiemetic effects in postoperative
      period  via plasma prostaglandin F2 alpha (PGF2 α) and plasma leukotriene C4 (LTC4)
      inhibition.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of participants will be evaluated to show effect of dexamethasone in reducing postoperative emesis</measure>
    <time_frame>up to 3 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>participants will be followed for the duration of hospital stay, till they are discharged in avarage 3 days for postoperative emesis.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Thyroid Cancer</condition>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing thyroidectomy and mastectomy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  breast and thyroid cancer patients no neoadjuvant treated no NSAID or steroid usage
             heallthy volunteers, signed the informed consent

        Exclusion Criteria:

          -  ones who did not sign the consent form NSAID or steroid users
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A.Ozdemir Aktan, MD,prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marmara University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marmara University School of Medicine</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 12, 2013</lastchanged_date>
  <firstreceived_date>March 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Marmara University</investigator_affiliation>
    <investigator_full_name>A.Ozdemir Aktan</investigator_full_name>
    <investigator_title>professor of surgery</investigator_title>
  </responsible_party>
  <keyword>Thyroid cancer</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Emesis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
